Cytokinetics reported positive late-stage clinical trial results for aficamten, a cardiac myosin inhibitor, showing improved exercise capacity in patients with obstructive hypertrophic cardiomyopathy (HCM) compared to standard beta blocker treatment. The Phase 3 MAPLE-HCM study demonstrated a 1.1-point increase in peak oxygen uptake with aficamten versus a decline in the metoprolol group. These results suggest potential for aficamten to become a new standard of care in HCM treatment, pending regulatory review.